163 related articles for article (PubMed ID: 35382522)
1. Selexipag treatment in patients with systemic sclerosis-associated pulmonary arterial hypertension in clinical practice, a case series.
Lemmers JM; Fretheim H; Knaapen HK; van den Hoogen FH; van Haren-Willems JH; Duijnhouwer AL; van Dijk AP; van den Ende CH; Hoffmann-Vold AM; Vonk MC
J Scleroderma Relat Disord; 2020 Oct; 5(3):NP7-NP11. PubMed ID: 35382522
[TBL] [Abstract][Full Text] [Related]
2. Selexipag for the treatment of children with pulmonary arterial hypertension: First multicenter experience in drug safety and efficacy.
Hansmann G; Meinel K; Bukova M; Chouvarine P; Wåhlander H; Koestenberger M;
J Heart Lung Transplant; 2020 Jul; 39(7):695-706. PubMed ID: 32362477
[TBL] [Abstract][Full Text] [Related]
3. Impact of different sequential triple oral combination therapies based selexipag on outcomes in pulmonary arterial hypertension.
Hu X; Yuan P; Chen J; Wang S; Zhao H; Wei Y; Fu J; Chen F; Ruan H; Zhang W; Zhou Y; Wang Q; Xu X; Feng K; Guo J; Gong S; Zhang R; Zhao Q; Wang L
Clin Cardiol; 2024 Feb; 47(2):e24245. PubMed ID: 38402556
[TBL] [Abstract][Full Text] [Related]
4. Selexipag for the Treatment of Pediatric Pulmonary Hypertension: A Systematic Review.
Li M; Liu L; Liu C; Chen Z; Li W; Li X; Ma X; Zhang Y
Clin Ther; 2024 Jan; 46(1):59-68. PubMed ID: 37945502
[TBL] [Abstract][Full Text] [Related]
5. Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study.
Frost A; Janmohamed M; Fritz JS; McConnell JW; Poch D; Fortin TA; Miller CE; Chin KM; Fisher M; Eggert M; McEvoy C; Benza RL; Farber HW; Kim NH; Pfister T; Shiraga Y; McLaughlin V
J Heart Lung Transplant; 2019 Jan; 38(1):43-50. PubMed ID: 30391194
[TBL] [Abstract][Full Text] [Related]
6. Prostacyclin for pulmonary arterial hypertension.
Barnes H; Yeoh HL; Fothergill T; Burns A; Humbert M; Williams T
Cochrane Database Syst Rev; 2019 May; 5(5):CD012785. PubMed ID: 31042010
[TBL] [Abstract][Full Text] [Related]
7. Selexipag for the Treatment of Pulmonary Arterial Hypertension.
Sitbon O; Channick R; Chin KM; Frey A; Gaine S; Galiè N; Ghofrani HA; Hoeper MM; Lang IM; Preiss R; Rubin LJ; Di Scala L; Tapson V; Adzerikho I; Liu J; Moiseeva O; Zeng X; Simonneau G; McLaughlin VV;
N Engl J Med; 2015 Dec; 373(26):2522-33. PubMed ID: 26699168
[TBL] [Abstract][Full Text] [Related]
8. Real-Life Experience with Selexipag as an Add-On Therapy to Oral Combination Therapy in Patients with Pulmonary Arterial or Distal Chronic Thromboembolic Pulmonary Hypertension: A Retrospective Analysis.
Berlier C; Schwarz EI; Saxer S; Lichtblau M; Ulrich S
Lung; 2019 Jun; 197(3):353-360. PubMed ID: 30963265
[TBL] [Abstract][Full Text] [Related]
9. Clinical efficacy and safety of selexipag in children and young adults with idiopathic and heritable pulmonary arterial hypertension.
Takatsuki S; Nakayama T; Shimizu Y; Kawai R; Matsuura H
Cardiol Young; 2023 Feb; 33(2):196-200. PubMed ID: 35383553
[TBL] [Abstract][Full Text] [Related]
10. Selexipag-based triple combination therapy improves prognosis in Chinese pulmonary arterial hypertension patients.
Cui X; Lu W; Zhang D; Qie L; Li H; Li X; Liu H; Ji Q
Front Cardiovasc Med; 2022; 9():991586. PubMed ID: 36204579
[TBL] [Abstract][Full Text] [Related]
11. Transition from epoprostenol to selexipag in a patient with systemic sclerosis and pulmonary hypertension during the postoperative period of colon cancer surgery: A case report.
Wada TT; Yokota K; Iida S; Kanno Y; Shinozuka N; Sato K; Asanuma YF; Yamamoto K; Mimura T
J Scleroderma Relat Disord; 2022 Jun; 7(2):NP4-NP8. PubMed ID: 35585949
[TBL] [Abstract][Full Text] [Related]
12. Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension.
Chin KM; Rubin LJ; Channick R; Di Scala L; Gaine S; Galiè N; Ghofrani HA; Hoeper MM; Lang IM; McLaughlin VV; Preiss R; Simonneau G; Sitbon O; Tapson VF
Circulation; 2019 May; 139(21):2440-2450. PubMed ID: 30982349
[TBL] [Abstract][Full Text] [Related]
13. Patient and disease characteristics of the first 500 patients with pulmonary arterial hypertension treated with selexipag in real-world settings from SPHERE.
Kim NH; Hemnes AR; Chakinala MM; Highland KB; Chin KM; McLaughlin V; Zhao C; Narayan V; Farber HW
J Heart Lung Transplant; 2021 Apr; 40(4):279-288. PubMed ID: 33526303
[TBL] [Abstract][Full Text] [Related]
14. Hemodynamic and clinical effects of selexipag in children with pulmonary hypertension.
Rothman A; Cruz G; Evans WN; Restrepo H
Pulm Circ; 2020; 10(1):2045894019876545. PubMed ID: 32110381
[TBL] [Abstract][Full Text] [Related]
15. A Canadian, retrospective, multicenter experience with selexipag for a heterogeneous group of pediatric pulmonary hypertension patients.
Youssef D; Richards S; Lague S; Sheppard C; Smith J; Vorhies E; Hosking M; Pietrosanu M; Bates A
Front Pediatr; 2023; 11():1055158. PubMed ID: 36925667
[TBL] [Abstract][Full Text] [Related]
16. A Case Report of a Patient With Pulmonary Arterial Hypertension Transitioned From Inhaled Iloprost to Selexipag.
Verlinden NJ; Walter C; Raina A; Benza RL
J Pharm Pract; 2021 Dec; 34(6):980-983. PubMed ID: 32912036
[TBL] [Abstract][Full Text] [Related]
17. Digital Tracking of Physical Activity, Heart Rate, and Inhalation Behavior in Patients With Pulmonary Arterial Hypertension Treated With Inhaled Iloprost: Observational Study (VENTASTEP).
Stollfuss B; Richter M; Drömann D; Klose H; Schwaiblmair M; Gruenig E; Ewert R; Kirchner MC; Kleinjung F; Irrgang V; Mueller C
J Med Internet Res; 2021 Oct; 23(10):e25163. PubMed ID: 34623313
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of an Orally Administered Selective Prostacyclin Receptor Agonist, Selexipag, in Japanese Patients With Pulmonary Arterial Hypertension.
Tanabe N; Ikeda S; Tahara N; Fukuda K; Hatano M; Ito H; Nakayama T; Anzai T; Hashimoto A; Inoue T; Kajinami K; Kihara Y; Kinoshita H; Kuwahara K; Murohara T; Okazaki O; Sakai S; Satoh T; Takeda Y; Takeishi Y; Taniguchi M; Watanabe H; Yamamoto T; Yamauchi-Takihara K; Yoshioka K; Sasayama S
Circ J; 2017 Aug; 81(9):1360-1367. PubMed ID: 28420826
[TBL] [Abstract][Full Text] [Related]
19. Triple oral combination therapy with macitentan, riociguat, and selexipag for pulmonary arterial hypertension.
Momoi M; Hiraide T; Shinya Y; Momota H; Fukui S; Kawakami M; Itabashi Y; Fukuda K; Kataoka M
Ther Adv Respir Dis; 2021; 15():1753466621995048. PubMed ID: 33627044
[TBL] [Abstract][Full Text] [Related]
20. Selexipag for the treatment of pulmonary arterial hypertension.
Richter MJ; Gall H; Grimminger J; Grimminger F; Ghofrani HA
Expert Opin Pharmacother; 2016 Sep; 17(13):1825-34. PubMed ID: 27467883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
